David L. Ennist
Novartis
TransgeneGeneGenetic enhancementMachine learningInternal medicineMolecular biologyArtificial intelligenceVirologyIntensive care medicineSubgroup analysisImmunologyRegulatory sequenceVirusAmyotrophic lateral sclerosisViral vectorComputer scienceCancer researchClinical trialMedicineOncolytic virusBiologyImmune systemPhysical medicine and rehabilitation
46Publications
16H-index
2,076Citations
Publications 47
Newest
#1Danielle BeaulieuH-Index: 3
#2Jonavelle CuerdoH-Index: 1
Last. David L. EnnistH-Index: 16
view all 3 authors...
Source
#1Albert A. TaylorH-Index: 5
#2Danielle BeaulieuH-Index: 3
Last. David L. EnnistH-Index: 16
view all 7 authors...
Source
#1Benjamin Rix BrooksH-Index: 54
#2Erik P. Pioro (Cleveland Clinic)H-Index: 20
Last. David L. EnnistH-Index: 16
view all 10 authors...
Introduction: The edaravone development program for amyotrophic lateral sclerosis (ALS) included trials MCI186-16 (Study 16) and MCI186-19 (Study 19). A cohort enrichment strategy was based on a Study 16 post hoc analysis and applied to Study 19 to elucidate a treatment effect in that study. To determine whether the Study 19 results could be generalized to a broader ALS population, we used a machine learning (ML) model to create a novel risk-based subgroup analysis tool. Methods: A validated ML ...
Source
#1Danielle BeaulieuH-Index: 3
#2Albert A. TaylorH-Index: 5
Last. David L. EnnistH-Index: 16
view all 7 authors...
Abstract Neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), are characterized by heterogeneous disease progression. As a group, these complex diseases are likely influenced by an interplay between numerous genetic and environmental factors. Drug development for these diseases could benefit from a statistical framework capable of efficiently stratifying participants using information avai...
Source
#1Danielle BeaulieuH-Index: 3
#2James D. Berry (Harvard University)H-Index: 29
Last. David L. EnnistH-Index: 16
view all 8 authors...
Introduction: Vital capacity (VC) is routinely used for ALS clinical trial eligibility determinations, often to exclude patients unlikely to survive trial duration. However, spirometry has been limited by the COVID-19 pandemic. We developed a machine-learning survival model without the use of baseline VC and asked whether it could stratify clinical trial participants and a wider ALS clinic population. Methods. A gradient boosting machine survival model lacking baseline VC (VC-Free) was trained u...
Source
#1Danielle BeaulieuH-Index: 3
#2Albert A. TaylorH-Index: 5
Last. David L. EnnistH-Index: 16
view all 7 authors...
Source
#1David A. Schoenfeld (Harvard University)H-Index: 124
#2Dianne M. Finkelstein (Harvard University)H-Index: 85
Last. Nazem Atassi (Harvard University)H-Index: 26
view all 7 authors...
Background/AimsFor single arm trials, a treatment is evaluated by comparing an outcome estimate to historically reported outcome estimates. Such a historically controlled trial is often analyzed as...
Source
#1Danielle BeaulieuH-Index: 3
#2Jonavelle CuerdoH-Index: 1
Last. David L. EnnistH-Index: 16
view all 8 authors...
Source
#1Danielle BeaulieuH-Index: 3
#2Albert A. TaylorH-Index: 5
Last. David L. EnnistH-Index: 16
view all 6 authors...
Source
#1Danielle BeaulieuH-Index: 3
#2Albert A. TaylorH-Index: 5
Last. David L. EnnistH-Index: 16
view all 6 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.